All Articles

Federal health officials this week allowed a genetic testing firm to sell kits to consumers to test whether they carry gene mutations that put them at higher risk for breast and ovarian cancer.

JONS Editor in Chief, Lillie Shockney, RN, BS, MAS, ONN-CG, offers her insights on the timely topic of commercially available genetic testing.

The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.

Updated NCCN Breast Cancer Guidelines

The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.

NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.

These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.

Ms Shockney discusses the importance of clinical trials and extends an invitation to apply to the AONN+ Clinical Trials Committee.

JONS talks to Ms Allison and Ms Melton about their experiences as navigators, the critical touch points they have with patients, and how coordinating care is executed at their institutions.

An Interview with Oncology Financial Navigator Clara Lambert of Cowell Family Cancer Center